Empagliflozin Is Associated with Increased Plasma Lipid Metabolites in Type 1 Diabetes
Hongyan Liu(University of Toronto), David Z.I. Cherney(University Health Network), Leif Erik Lovblom(Mount Sinai Hospital), Hongping Ye(The University of Texas at San Antonio Health Science Center), Daniel Montemayor(The University of Texas at San Antonio Health Science Center), Yuliya Lytvyn(University Health Network), Bruce A. Perkins(Sinai Health System), Kumar Sharma(The University of Texas at San Antonio Health Science Center), Daniel Scarr(Mount Sinai Hospital)
Cited by 0
Related Papers
The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight
|Science|2019|1.1k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Metabolomics Reveals Signature of Mitochondrial Dysfunction in Diabetic Kidney Disease
|Journal of the American Society of Nephrology|2013|578
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470
Sex-Related Disparities in CKD Progression
|Journal of the American Society of Nephrology|2018|299